ArticleFrontiers in oncology2019
The
Open access · goldAbstract read
In one paragraph
Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Impact of Metformin on Cancer Biomarkers in Non-Diabetic Cancer Patients: A Systematic Review and Meta-Analysis of Clinical Trials.Current oncology (Toronto, Ont.) · 2021Pooled it
- Exploration of body mass index and circulating metabolic factors as predictors of metformin benefit in the Canadian Cancer Trials Group MA.32.JNCI cancer spectrum · 2026Trial
- Trial
- Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo.JNCI cancer spectrum · 2021Trial
- The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32.Journal of the National Cancer Institute · 2021Trial
- Trial
- Metformin for the treatment of breast cancer: a scoping review of randomized clinical trials.BMC cancer · 2025Article
- Metabolic stress-mediated cell death and autophagy in human lung cancer cells.The Journal of pharmacology and experimental therapeutics · 2025Article
- Metformin: A Dual-Role Player in Cancer Treatment and Prevention.International journal of molecular sciences · 2024Review
- Review
- Metformin and its potential influence on cell fate decision between apoptosis and senescence in cancer, with a special emphasis on glioblastoma.Frontiers in oncology · 2024Review
- Clinical significance of lipid pathway-targeted therapy in breast cancer.Frontiers in pharmacology · 2024Article
- Recent Progress in the Diagnosis and Management of Type 2 Diabetes Mellitus in the Era of COVID-19 and Single Cell Multi-Omics Technologies.Life (Basel, Switzerland) · 2022Review
- Article
- Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial.NPJ breast cancer · 2021Article
- Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer.Therapeutic advances in medical oncology · 2021Article
- Association between ABC family variants rs1800977, rs4149313, and rs1128503 and susceptibility to type 2 diabetes in a Chinese Han population.The Journal of international medical research · 2020Article
- Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer.Journal of clinical medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 14 institutions in 1 country.
Elisabet CuyàsProgram Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Spain.
Maria BuxóGirona Biomedical Research Institute (IDIBGI), Girona, Spain.
Maria José Ferri IglesiasLaboratori Clínic Territorial, Parque Hospitalario Martí i Julià, Salt, Spain.
Sara VerduraProgram Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Spain.
Sonia PernasBreast Unit, Department of Medical Oncology, Catalan Institute of Oncology-Hospital Universitari de Bellvitge-Bellvitge Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Joan DorcaMedical Oncology, Catalan Institute of Oncology, Girona, Spain.
Isabel ÁlvarezMedical Oncology Service, Hospital Universitario Donostia, Donostia-San Sebastián, Spain.
Susana MartínezMedical Oncology Department, Hospital de Mataró, Mataró, Barcelona, Spain.
Jose Manuel Pérez-GarciaHospital Quirón, IOB Institute of Oncology, Barcelona, Spain.
Norberto Batista-LópezMedical Oncology Service, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain.
César A Rodríguez-SánchezMedical Oncology Service, Hospital Universitario de Salamanca, Salamanca, Spain.
Kepa AmillanoMedical Oncology, Hospital Universitari Sant Joan, Reus, Spain.
Severina DomínguezMedical Oncology Service, Hospital Universitario Araba, Vitoria-Gasteiz, Spain.
Maria LuqueDepartment of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain.
Idoia MorillaBreast Unit, Department of Medical Oncology, Catalan Institute of Oncology-Hospital Universitari de Bellvitge-Bellvitge Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Agostina StradellaBreast Unit, Department of Medical Oncology, Catalan Institute of Oncology-Hospital Universitari de Bellvitge-Bellvitge Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Gemma ViñasMedical Oncology, Catalan Institute of Oncology, Girona, Spain.
Javier CortésDepartment of Medical Oncology, Ramón y Cajal University Hospital, Madrid, Spain.
Jorge JovenUnitat de Recerca Biomèdica, Hospital Universitari de Sant Joan, IISPV, Rovira i Virgili University, Reus, Spain.
Joan BrunetMedical Oncology, Catalan Institute of Oncology, Girona, Spain.
Eugeni López-BonetDepartment of Anatomical Pathology, Dr. Josep Trueta Hospital of Girona, Girona, Spain.
Margarita GarciaClinical Research Unit, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain.
Samiha SaidaniUnit of Clinical Research, Catalan Institute of Oncology, Girona, Spain.
Xavier Queralt MolesLaboratori Clínic Territorial, Parque Hospitalario Martí i Julià, Salt, Spain.
Begoña Martin-CastilloUnit of Clinical Research, Catalan Institute of Oncology, Girona, Spain.
Javier A MenendezProgram Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Spain.
Catalan Institute for Water Research · ESInstitut d'Investigació Biomèdica de Girona · ESBellvitge University Hospital · ESInstitut Català d'Oncologia · ESBiogipuzkoa Health Research Institute · ESHospital de Mataró · ESHospital Universitari de Girona Doctor Josep Trueta · ESHospital Universitario Araba · ESHospital Universitario Central de Asturias · ESHospital Universitario de Canarias · ESHospital Universitari Sant Joan de Reus · ESInstituto Cajal · ESInstituto de Investigación Biomédica de Salamanca · ESUniversitat Rovira i Virgili · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
ATMbreast cancerHER2metforminneoadjuvancyrs11212617
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.